Raymond James & Associates Relay Therapeutics, Inc. Call Options Transaction History
Raymond James & Associates
- $161 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RLAY
# of Institutions
204Shares Held
156MCall Options Held
207KPut Options Held
40K-
Sb Investment Advisers (Uk) LTD London, X027.9MShares$133 Million1.63% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.5MShares$68.7 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.5MShares$50.1 Million0.0% of portfolio
-
Casdin Capital, LLC New York, NY9.25MShares$43.9 Million5.09% of portfolio
-
Bellevue Group Ag Kuesnacht, V87.38MShares$35 Million0.88% of portfolio
About Relay Therapeutics, Inc.
- Ticker RLAY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 120,219,000
- Market Cap $571M
- Description
- Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhib...